Why it matters:
Conor Ryder, a man living with Tourette syndrome, is advocating for greater access to medicinal cannabis through the National Health Service (NHS) in the UK. Currently, Ryder has to pay for private prescriptions as the NHS lacks availability. This article highlights the struggle faced by patients like Ryder and the potential benefits of cannabis for treating Tourette syndrome.
What they are saying:
Ryder is urging the government to make medicinal cannabis more accessible through the NHS, as it is the only treatment that effectively manages his severe tics. Despite medical marijuana being legalized in the UK in 2018, the government requires more research to ensure its safety before expanding access. Private cannabis clinics have grown since legalization but are often unaffordable for patients like Ryder.
The big picture:
Research suggests that cannabis can improve the side-effect profile of Tourette syndrome by reducing tics. However, access to medicinal cannabis through the NHS remains limited due to safety concerns. The private sector of the cannabis industry has seen growth, but affordability is a significant issue for patients.
What to watch:
Watch for potential changes in the UK’s stance on medicinal cannabis for treating Tourette syndrome. If further research establishes its safety and effectiveness, there may be increased access through the NHS. Additionally, keep an eye on the affordability of cannabis prescriptions for patients like Ryder.
My take:
It is important for patients like Conor Ryder to have access to affordable and effective treatments for managing their conditions. While the government’s cautious approach due to safety concerns is valid, it is crucial to prioritize the well-being of patients and explore options like medicinal cannabis with proper research and regulation. Access to affordable medicinal cannabis through the NHS can significantly improve the quality of life for individuals living with Tourette syndrome.
